BRPI0921868A2 - inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica - Google Patents

inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica

Info

Publication number: BRPI0921868A2
Authority: BR; Brazil
Prior art keywords: iii; inhibitors; treatment; hypertrophic cardiomyopathy; phosphodiesterase type
Prior art date: 2008-11-25

Application number

BRPI0921868A

Other languages

English (en)

Inventor

Juergen Daemmgen

Olaf Joens

Original Assignee

Boehringer Ingelheim Vetmed

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-25

Filing date

2009-11-23

Publication date

2015-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40491062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0921868(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-23 Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed

2015-12-29 Publication of BRPI0921868A2 publication Critical patent/BRPI0921868A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0921868A 2008-11-25 2009-11-23 inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica BRPI0921868A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08169897		2008-11-25
PCT/EP2009/065618 WO2010060874A1 (en)	2008-11-25	2009-11-23	Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy

Publications (1)

Publication Number	Publication Date
BRPI0921868A2 true BRPI0921868A2 (pt)	2015-12-29

Family

ID=40491062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0921868A BRPI0921868A2 (pt)	2008-11-25	2009-11-23	inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica

Country Status (24)

Country	Link
US (1)	US8664252B2 (pt)
EP (3)	EP2702987A1 (pt)
JP (1)	JP5643213B2 (pt)
KR (1)	KR20110089851A (pt)
CN (1)	CN102223882B (pt)
AR (1)	AR074214A1 (pt)
AU (1)	AU2009319076A1 (pt)
BR (1)	BRPI0921868A2 (pt)
CA (1)	CA2744505A1 (pt)
CL (1)	CL2011001026A1 (pt)
CO (1)	CO6400188A2 (pt)
CY (1)	CY1114791T1 (pt)
DK (1)	DK2370070T3 (pt)
ES (1)	ES2436716T3 (pt)
HR (1)	HRP20131150T1 (pt)
MX (1)	MX2011005444A (pt)
NZ (1)	NZ592927A (pt)
PL (1)	PL2370070T3 (pt)
PT (1)	PT2370070E (pt)
SG (1)	SG171783A1 (pt)
SI (1)	SI2370070T1 (pt)
TW (1)	TW201026684A (pt)
WO (1)	WO2010060874A1 (pt)
ZA (1)	ZA201103108B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102004011512B4 (de)	2004-03-08	2022-01-13	Boehringer Ingelheim Vetmedica Gmbh	Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en)	2004-03-25	2005-09-28	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en)	2004-03-25	2015-03-17	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en)	2006-11-07	2008-05-14	Boehringer Ingelheim Vetmedica Gmbh	Liquid preparation comprising a complex of pimobendan and cyclodextrin
US10398705B2 (en)	2012-03-15	2019-09-03	Boehringer Ingelheim Vetmedica Gmbh	Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
AU2014292086B2 (en)	2013-07-19	2019-08-08	Boehringer Ingelheim Vetmedica Gmbh	Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
MX375936B (es)	2013-12-04	2025-03-07	Boehringer Ingelheim Vetmedica Gmbh	Composiciones farmaceuticas mejoradas de pimobendan.
US10537570B2 (en)	2016-04-06	2020-01-21	Boehringer Ingelheim Vetmedica Gmbh	Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
WO2022073954A1 (en)	2020-10-08	2022-04-14	Boehringer Ingelheim Vetmedica Gmbh	Use of pimobendan in the anaesthesia of non-human mammals

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES8101067A1 (es)	1978-08-25	1980-12-01	Thomae Gmbh Dr K	Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
DE3237575A1 (de)	1982-10-09	1984-04-12	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue orale mopidamolformen
DE3346123A1 (de)	1983-12-21	1985-06-27	Janssen Pharmaceutica, N.V., Beerse	Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8400863D0 (en)	1984-01-13	1984-02-15	Smith Kline French Lab	Chemical compounds
US6407079B1 (en)	1985-07-03	2002-06-18	Janssen Pharmaceutica N.V.	Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
DE3677316D1 (de)	1985-10-17	1991-03-07	Smith Kline French Lab	4(4-oxo-1,4-dihydropyridin-1-yl)phenyl-derivate.
US4868182A (en)	1986-11-05	1989-09-19	Merrell Dow Pharmaceuticals Inc.	Enhancement of prazosin
DE3728244A1 (de)	1987-08-25	1989-03-09	Thomae Gmbh Dr K	Neue (-)-benzimidazole, deren herstellung und diese verbindungen enthaltende arzneimittel
EP0306846A3 (de)	1987-09-11	1990-05-02	Dr. Karl Thomae GmbH	Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Thromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung
US5002935A (en)	1987-12-30	1991-03-26	University Of Florida	Improvements in redox systems for brain-targeted drug delivery
DE3804490A1 (de)	1988-02-12	1989-08-24	Heumann Pharma Gmbh & Co	Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3805635A1 (de)	1988-02-24	1989-09-07	Thomae Gmbh Dr K	Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
EP0335545B2 (en)	1988-03-29	1998-09-23	University Of Florida	Pharmaceutical formulations for parenteral use
GB8824458D0 (en)	1988-10-19	1988-11-23	Orion Yhtymae Oy	Substituted pyridazinones
GB8903130D0 (en)	1989-02-11	1989-03-30	Orion Yhtymae Oy	Substituted pyridazinones
US5364646A (en)	1990-01-10	1994-11-15	Dr. Karl Thomae Gmbh	Oral pharmaceutical forms of pimobendan
DE4001622A1 (de)	1990-01-20	1991-07-25	Thomae Gmbh Dr K	Orale arzneimittelformen von pimobendan
GB2251615B (en)	1991-01-03	1995-02-08	Orion Yhtymae Oy	(-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US6476078B2 (en)	1999-08-11	2002-11-05	Sepracor, Inc.	Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
EP1311292A2 (en)	2000-06-21	2003-05-21	Bristol-Myers Squibb Pharma Company	Vitronectin receptor antagonist pharmaceuticals
ES2292598T3 (es)	2000-06-27	2008-03-16	Vectura Limited	Metodo para producir particulas para usar en una composicion farmaceutica.
EP1363898A4 (en)	2001-03-02	2004-12-08	Bristol Myers Squibb Co	COMPOUNDS SUITABLE AS MODULATORS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE60237696D1 (de)	2001-08-01	2010-10-28	Univ Utah	Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
DE10228049A1 (de)	2002-06-24	2004-01-15	Merck Patent Gmbh	Flüssige Zubereitung enthaltend Oligopeptide
US20040037869A1 (en)	2002-08-16	2004-02-26	Douglas Cleverly	Non-animal product containing veterinary formulations
EP1554267A1 (en) *	2002-10-07	2005-07-20	Artesian Therapeutics, Inc.	Dihydropyridine compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity
CA2506741A1 (en)	2002-11-27	2004-06-17	Artesian Therapeutics, Inc.	Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure
AU2003300297A1 (en)	2002-12-23	2004-07-22	Artesian Therapeutics, Inc.	CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST Beta-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
WO2005035505A2 (en)	2003-09-30	2005-04-21	Artesian Therapeutics, Inc.	Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
DE102004011512B4 (de)	2004-03-08	2022-01-13	Boehringer Ingelheim Vetmedica Gmbh	Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en)	2004-03-25	2015-03-17	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) *	2004-03-25	2005-09-28	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
JP2005281283A (ja)	2004-03-31	2005-10-13	Akira Matsumori	ベンズイミダゾール系薬剤の併用医薬
FI20040675A0 (fi)	2004-05-12	2004-05-12	Orion Corp	Menetelmä sydämen hypertrofian hoitoon ja estoon
NZ534939A (en)	2004-08-26	2007-04-27	Bomac Research Ltd	Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
US20080090827A1 (en)	2004-11-30	2008-04-17	Artesian Therapeutics, Inc.	Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
JP2008521805A (ja) *	2004-11-30	2008-06-26	アーテシアンセラピューティクス，インコーポレイテッド	β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物
CN1702243A (zh)	2005-05-31	2005-11-30	刘坚雄	无壁板框架结构装配组合式房屋建筑及其建造方法
DK1951227T3 (en)	2005-11-14	2017-07-10	Boehringer Ingelheim Vetmedica Gmbh	APPLICATION OF PIMOBENDAN TO TREAT ASYMPTOMATIC (OCCULT) HEART FAILURE
EP1920785A1 (en)	2006-11-07	2008-05-14	Boehringer Ingelheim Vetmedica Gmbh	Liquid preparation comprising a complex of pimobendan and cyclodextrin

2009
- 2009-11-23 WO PCT/EP2009/065618 patent/WO2010060874A1/en not_active Ceased
- 2009-11-23 AU AU2009319076A patent/AU2009319076A1/en not_active Abandoned
- 2009-11-23 PT PT97563118T patent/PT2370070E/pt unknown
- 2009-11-23 HR HRP20131150AT patent/HRP20131150T1/hr unknown
- 2009-11-23 EP EP13182286.8A patent/EP2702987A1/en not_active Withdrawn
- 2009-11-23 JP JP2011536885A patent/JP5643213B2/ja not_active Expired - Fee Related
- 2009-11-23 EP EP13182285.0A patent/EP2702986A1/en not_active Withdrawn
- 2009-11-23 ES ES09756311.8T patent/ES2436716T3/es active Active
- 2009-11-23 EP EP09756311.8A patent/EP2370070B9/en active Active
- 2009-11-23 CA CA2744505A patent/CA2744505A1/en not_active Abandoned
- 2009-11-23 KR KR1020117011533A patent/KR20110089851A/ko not_active Withdrawn
- 2009-11-23 NZ NZ592927A patent/NZ592927A/xx not_active IP Right Cessation
- 2009-11-23 SI SI200930760T patent/SI2370070T1/sl unknown
- 2009-11-23 US US13/126,541 patent/US8664252B2/en active Active
- 2009-11-23 MX MX2011005444A patent/MX2011005444A/es active IP Right Grant
- 2009-11-23 SG SG2011036803A patent/SG171783A1/en unknown
- 2009-11-23 PL PL09756311T patent/PL2370070T3/pl unknown
- 2009-11-23 BR BRPI0921868A patent/BRPI0921868A2/pt not_active IP Right Cessation
- 2009-11-23 DK DK09756311.8T patent/DK2370070T3/da active
- 2009-11-23 CN CN200980146944.7A patent/CN102223882B/zh not_active Expired - Fee Related
- 2009-11-24 TW TW098139973A patent/TW201026684A/zh unknown
- 2009-11-24 AR ARP090104533A patent/AR074214A1/es unknown
2011
- 2011-04-28 ZA ZA2011/03108A patent/ZA201103108B/en unknown
- 2011-05-06 CL CL2011001026A patent/CL2011001026A1/es unknown
- 2011-05-24 CO CO11063885A patent/CO6400188A2/es not_active Application Discontinuation
2013
- 2013-11-18 CY CY20131101017T patent/CY1114791T1/el unknown

Also Published As

Publication number	Publication date
DK2370070T3 (da)	2013-12-02
EP2702987A1 (en)	2014-03-05
ES2436716T3 (es)	2014-01-03
MX2011005444A (es)	2011-06-09
JP2012509858A (ja)	2012-04-26
AU2009319076A1 (en)	2010-06-03
SG171783A1 (en)	2011-07-28
EP2370070B1 (en)	2013-09-04
NZ592927A (en)	2013-07-26
EP2370070A1 (en)	2011-10-05
AR074214A1 (es)	2010-12-29
CA2744505A1 (en)	2010-06-03
CY1114791T1 (el)	2016-12-14
PT2370070E (pt)	2013-11-18
US8664252B2 (en)	2014-03-04
ZA201103108B (en)	2014-03-26
KR20110089851A (ko)	2011-08-09
SI2370070T1 (sl)	2013-12-31
CL2011001026A1 (es)	2011-09-02
HRP20131150T1 (hr)	2014-01-03
CN102223882A (zh)	2011-10-19
JP5643213B2 (ja)	2014-12-17
PL2370070T3 (pl)	2014-02-28
CO6400188A2 (es)	2012-03-15
US20110251208A1 (en)	2011-10-13
TW201026684A (en)	2010-07-16
CN102223882B (zh)	2016-02-03
EP2702986A1 (en)	2014-03-05
EP2370070B9 (en)	2014-04-23
WO2010060874A1 (en)	2010-06-03

Legal Events

Date	Code	Title	Description
2017-09-19	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-01-09	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Publication	Publication Date	Title
SMT201600267B (it)	2016-08-31	Inibitori di syk imidazopirazinici
DK2389382T3 (da)	2013-07-08	Aminoheterocykliske forbindelser anvendt som pde9-inhibitorer
EP2299999A4 (en)	2012-01-25	STAT3 INHIBITORS
EP2272817A4 (en)	2011-12-14	PAI-1 INHIBITORS
LTPA2017039I1 (lt)	2017-12-11	Pirolopirimidino junginiai, kaip CDK inhibitoriai
DK3354650T3 (da)	2022-05-30	Forbindelser der er nyttige som inhibitorer af ATR-kinase
EP2192838A4 (en)	2011-07-27	HETEROCYCLIC NEKROPTOSIS HEMMER
DK2364308T3 (da)	2013-02-04	Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10
BRPI0716981A2 (pt)	2013-10-15	Inibidores de cinase úteis para o tratamento de doenças proliferativas
EP2278969A4 (en)	2011-10-05	JANUS KINASE INHIBITORS
EP2421867A4 (en)	2012-10-10	PIPERIDINIC INHIBITORS OF JANUS KINASE 3
EP2299816A4 (en)	2012-07-04	JANUS KINASE INHIBITORS
EP2231143A4 (en)	2010-12-22	JANUS KINASE INHIBITORS
EP2346508A4 (en)	2012-04-18	HETEROCYCLIC KINASE HEMMER
MA32938B1 (fr)	2012-01-02	Composes organiques
EA201100037A1 (ru)	2011-08-30	Органические соединения
EP2166846A4 (en)	2011-03-23	JANUS KINASE INHIBITORS
BRPI0911764A2 (pt)	2015-10-06	inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
PL3354276T3 (pl)	2020-09-21	Kompozycje do leczenia zapalenia przewodu pokarmowego
HRP20150003T1 (xx)	2015-03-13	Sastavi inhibitora dpp-iv
BRPI0817096A2 (pt)	2017-05-02	análogos de tiazolidinodiona para o tratamento de hipertensão
BRPI0915231A2 (pt)	2018-06-12	compostos inibidores de quinase e métodos de uso
NO345061B1 (no)	2020-09-14	Anvendelse av DPP-IV inhibitorer
EP2310384A4 (en)	2012-02-22	JANUS KINASE INHIBITORS
SV2009003373A (es)	2010-08-10	COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759